Sacubitril/Valsartan Does Not Change the Use and Dose of Loop Diuretics in Patients With Heart Failure With Reduced Ejection Fraction.

Autor:	Kido K; Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, WV, USA., Bianco C; Division of Cardiology, Department of Medicine, West Virginia University, Morgantown, Morgantown, WV, USA., Caccamo M; Division of Cardiology, Department of Medicine, West Virginia University, Morgantown, Morgantown, WV, USA., Hashiguchi M; Tokyo Jikei University School of Medicine, Tokyo, Japan., Choo LY; Clinical and Translational Science, West Virginia University, Morgantown, WV, USA., Sokos G; Division of Cardiology, Department of Medicine, West Virginia University, Morgantown, Morgantown, WV, USA.
Jazyk:	angličtina
Zdroj:	Journal of pharmacy practice [J Pharm Pract] 2024 Jun; Vol. 37 (3), pp. 708-711. Date of Electronic Publication: 2023 May 16.
DOI:	10.1177/08971900231177202
Abstrakt:	Background: There is no standard approach for managing the use or dose of loop diuretics after initiating sacubitril/valsartan. Objective: To investigate longitudinal trends in loop diuretic therapy use and doses during the initial 6 months following sacubitril/valsartan initiation. Methods: This retrospective cohort study included adult patients who were initiated on sacubitril/valsartan in cardiology clinics. Inclusion criteria were patients diagnosed with heart failure with reduced ejection fraction (ejection fraction ≤40%) and initiated on sacubitril/valsartan in an outpatient setting. We investigated longitudinal trends in the prevalence of loop diuretic use and furosemide equivalent dose at baseline, 2 weeks, 1 month, 3 month and 6 months following sacubitril/valsartan initiation. Results: A total of 427 patients were included in the final cohort. Compared to the baseline loop diuretic use and dose, there were no significant longitudinal changes in the prevalence of loop diuretic use or the furosemide equivalent dose over the 6 months following sacubitril/valsartan initiation. The use of sacubitril/valsartan was not significantly associated with reductions in the use or dose of loop diuretics over a 6-month follow-up period. Conclusion: The use of sacubitril/valsartan did not significantly change the use or dose of loop diuretics over 6-month follow-up period. Initiation of sacubitril/valsartan may not need a pre-emptive loop diuretic dose reduction. Competing Interests: Declaration of Conflicting InterestsGeorge Sokos was a speaker for Novartis Pharmaceutical sponsored presentation. Other authors declare no conflicts of interest. FundingThe authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number 5U54GM104942-04. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu